essentials glp-1 active physiology in obesity and development of incretin-based drugs for chronic weight management Decoding GLP-1 Weight Loss Medications
Description
The glucagon receptor family
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
PP: Writing original draft, Writing review & editing
The lack of superiority is probably attributable to the short follow-up period and high CVD risk in the enrolled subjects
Risk, however, is not uniform
Ultimately, starting any new medication comes with an adjustment period, and for some people on GLP-1 therapy, that adjustment may include headaches
